Nasdaq · Healthcare
EXPONENT INC (EXPO)
As-reported financials and recent SEC filings for EXPONENT INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$582.0M
Net income
$106.0M
Net margin
18.2%
Diluted EPS
$2.07
ROE
27.2%
P/E (TTM)
28.4×
Market cap
$2.95B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $582.0M | $558.5M | $536.8M | $513.3M | $466.3M |
| Gross profit | — | — | — | — | — |
| Operating income | $119.8M | $119.6M | $111.3M | $140.8M | $108.9M |
| Net income | $106.0M | $109.0M | $100.3M | $102.3M | $101.2M |
| Diluted EPS | $2.07 | $2.11 | $1.94 | $1.96 | $1.90 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-17
View on EDGAR →1442026-06-15
View on EDGAR →8-K2026-06-10
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →42026-06-04
View on EDGAR →Go deeper on EXPO
Search EXPONENT INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.